Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Oct 05, 2023 11:46am
71 Views
Post# 35671150

RE:Mental manipulation

RE:Mental manipulation

Growth in revenue and green eps: Q4 '23 and Q1 '24....ANVISA targeted approval timing and first big commercial contract for Brazil.   That will take us on hard financial numbers to at least the historical high of just over $7.   No fluff, hard core numbers and commercial contracts.   All news to date from LABS for over a year now has been positive including the big improvements in their balance sheet and cash position.  No fluff, hard core numbers speak louder than b.s.   

At the end of the day, it really doesn't matter what anyone thinks or says because what we are waiting for has been set in motion years ago, including the day Medipharm Labs began to exist as a company and being the first company as well focused on extraction for pharmaceutical applications...commercializing the life time work of Dr. Mechoulam et al.  

Clinical trials, scientific evidence that has no fluff, no b.s., hard core facts. 

Also, you were complaining a little bit that you only saw 6 clinical trials that LABS published in a press release.   Easy math says that at least 14 of those clinical trials that have not been disclosed are with their pharma partner and secretive for competitive reasons. 

Buy the sh*t out of it.  

<< Previous
Bullboard Posts
Next >>